UroGen Pharma Ltd.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item5. Other Information.
Rule10b5*-1 Trading Arrangements*
On* August 25, 2026,Stuart Holden, adirector of our Company, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule10b5*-1(c) under the Exchange Act, to sell up to 50,000 ordinary shares. The trading plan expires on* November 22, 2028.*
On* August 28, 2026,Arie S. Belldegrun, adirector of our Company, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule10b5*-1(c) under the Exchange Act, to sell up to 120,000 ordinary shares. The trading plan expires on* October 29, 2027.*
87
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.